FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder | Business Wire

FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder | Business Wire: Usona Institute's psilocybin program for major depressive disorder has received Breakthrough Therapy Designation from the US FDA.